

Palladium mediated C-O bond activation of benzopyrone in 4-oxo-4H-chromone-3-carbaldehyde-4(N)-substituted thiosemicarbazone: Synthesis, structure, nucleic acid/albumin interaction, DNA cleavage, antioxidant and cytotoxic studies

A. Shanmugapriya ^a, G. Kalaiarasi ^a, M. Ravi ^b, H. A. Sparkes ^c P. Kalaivani ^d and R. Prabhakaran^{a*}

^aDepartment of Chemistry, Bharathiar University, Coimbatore 641 046, India

^bDepartment of Biochemistry, University of Madras, Guindy Campus, Chennai - 25, India.

^cUniversity of Bristol, School of Chemistry, Cantock's Close, Bristol BS8 1TS, UK

^dDepartment of Chemistry, Nirmala College for Women, Bharathiar University, Coimbatore 641018, India

Supporting information

Fig.S1-S8. ¹H-NMR spectra of the ligands (**HL**¹⁻⁴) and complexes (**1-4**).

Fig.S9-S16. ¹³C-NMR spectra of the ligands (**HL**¹⁻⁴) and complexes (**1-4**).

Fig.S17-S19. ESI-MS spectra of the complexes **1**, **2** and **4**.

Fig. S20. Synchronous spectra of BSA (1×10^{-6} M) in the absence and presence of complexes **1-4** (0-100 μ M) in the wavelength difference of $\Delta\lambda = 60$ nm.

DNA binding studies

The experiments involving CT-DNA were performed in double distilled water with tris(hydroxymethyl)aminomethane (Tris, 5 mM) and sodium chloride (50 mM) and adjusted to pH 7.2 with hydrochloric acid. The concentration of CT-DNA was determined by UV absorbance at 260 nm. The molar absorption coefficient, $\epsilon_{\max 260}$, was taken as $6600 \text{ M}^{-1} \text{ cm}^{-1}$. CT-DNA solution of various concentrations (5-50 μM) dissolved in Tris-HCl (pH 7.2) were added to the nickel(II) complexes **1-4** (10 μM dissolved in a DMSO- H_2O mixture). Absorption spectra were recorded after equilibrium at 20 °C for 10 min. The intrinsic binding constant K_b was determined by using the Stern-Volmer equation (1).¹

$$([DNA] / [\epsilon_a - \epsilon_f]) = [DNA] / [\epsilon_b - \epsilon_f] + 1 / K_b[\epsilon_b - \epsilon_f] \quad (1)$$

The absorption coefficients ϵ_a , ϵ_f , and ϵ_b correspond to $A_{\text{obsd}}/[DNA]$, the extinction coefficient for the free complexes and the extinction coefficient for the complexes in the fully bound form, respectively. The intrinsic binding constant K_b can be obtained from the ratio of the slope to the intercept in plots of $[DNA] / [\epsilon_a - \epsilon_f]$ versus $[DNA]$.

Competitive binding with ethidium bromide

To find out the exact mode of attachment of CT-DNA to the complexes, fluorescence quenching experiments of EB-DNA were carried out by adding 10 μL portion of 10 μM nickel(II) complexes every time to the sample containing 10 μM EB, 10 μM DNA and Tris buffer (pH 7.2). Before the measurements, the system was shaken and incubated at room

temperature for ~5 min. The emission spectra were recorded at 530-750 nm. On the basis of the classical Stern-Volmer equation, the quenching constant has been analysed (2).

$$I_0/I = K_{sv}[Q] + 1 \quad (2)$$

Where I_0 and I represent the emission intensities in the absence and presence of the complexes, respectively, K_{sv} is the quenching constant, and $[Q]$ is the concentration ratio of the complex. The K_{sv} values have been obtained as a slope from the plot of I_0/I versus $[Q]$. Further, the apparent DNA binding constant (K_{app}) were calculated using the following equation,

$$K_{EB} [EB] = K_{app}[\text{complex}]$$

(Where $[\text{complex}]$ is the value at a 50% reduction in the fluorescence intensity of EB, K_{EB} ($1.0 \times 10^7 \text{ M}^{-1}$) is the DNA binding constant of EB, $[EB]$ is the concentration of EB = $10 \mu\text{M}$).

DNA cleavage studies

The cleavage of DNA was monitored by using agarose gel electrophoresis. Supercoiled pBR322 DNA (100 mg) in 5% DMSO and 95% Tris buffer (5 mM, pH 7.2) with 50 mM NaCl was incubated at 37°C in the absence and presence of compounds. The DNA, compound and sufficient buffer were premixed in a vial, and the reaction was allowed to proceed for 2 h at 37°C. The samples were then analyzed by 1.5% agarose gel electrophoresis in tris-acetic acid-ethylenediaminetetraacetic acid buffer. The gel was stained with $0.5 \mu\text{g cm}^{-3}$ ethidium bromide before migration. After electrophoresis at 50 V for 3 h, the gel was illuminated and the digital images were analyzed by gel documentation system (SYNGEN USA).²

Bovine serum albumin binding study

BSA solution ($10 \mu\text{M}$) was prepared in phosphate buffer of pH 7.2 and stored in the dark at 4 °C for use. The excitation wavelength of BSA at 280 nm and the emission at 346 nm were monitored for the protein binding studies. The excitation and emission slit widths and scan rates were maintained constant for all of the experiments. Concentrated stock solution of complexes were prepared by dissolving the compounds in DMSO and diluted suitably with deionised water to required concentrations for all the experiments (1% DMSO in the final solution). Quenching of the emission intensity of tryptophan residues of BSA at 346 nm (excitation wavelength at 276 nm) was monitored using compound as quenchers with

increasing compound concentration. The possible quenching mechanism has been interpreted using the Stern-Volmer equation (2).

When small molecule bind to the active site of BSA, the equilibrium binding constant and the number of binding sites can be analysed by using the Scatchard equation (4).

$$\log[(F_0 - F)/F] = \log K + n \log[Q] \quad (4)$$

Where K is the binding constant of quencher with BSA, n is the number of binding sites, F_0 and F are the fluorescence intensity in the absence and the presence of the quencher. Which can be determined by the slope and the intercept of the double logarithm regression curve of $\log [(F_0-F)/F]$ versus $\log[Q]$. Synchronous fluorescence spectra of BSA with various concentrations of complexes (0-100 μ M) were obtained from 300 to 500 nm when $\Delta\lambda = 60$ nm and from 290 to 500 nm when $\Delta\lambda = 15$ nm. The excitation and emission slit widths were 5 and 6 nm, respectively. Fluorescence and synchronous measurements were performed by using a 1 cm quartz cell on a JASCO FP 6600 spectrofluorometer.

Three dimension fluorescence spectra measurement

The 3D fluorescence spectra of BSA were recorded with and without complexes. Protein solution at 10 μ M was transferred to a quartz cell, diluted with 2.0 mL phosphate buffer and mixed well. To this, 10 μ M of complexes was added and the 3D fluorescence spectra were recorded by scanning excitation wavelength in the range of 200–350 nm and emission wavelength from 220 to 500 nm at an interval of 10 nm. The scanning parameters were the same as in the fluorescence quenching experiments.

Evaluation of antioxidant assays

DPPH radical scavenging activity

The potential antioxidant activity of ligands and new nickel(II) complexes (**1-4**) was evaluated by diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay was determined by Szabo method.³ DPPH free radicals are used for rapid analysis of antioxidants. While scavenging the free radicals, the antioxidants donate hydrogen and form a stable DPPH molecule. Briefly, the various concentrations of the complexes (20-100 μ g/ml) in 1 ml of 10 % aqueous DMSO were added to 5 ml of DPPH (0.1 mM in methanol) and were mixed rapidly. A negative control was prepared by adding 100 μ l of 10% aqueous DMSO in 5 mL of 0.1 mM methanolic solution of DPPH. Radical scavenging capacity was measured in 10

min intervals using spectrophotometer by monitoring the decrease in absorbance at 517 nm. The IC₅₀ values of DPPH decolorization of the complexes were calculated. Ascorbic acid was used as a positive control.

Nitric oxide scavenging assay⁴

The nitric oxide (NO) scavenging activity of the complexes has been investigated using the Green method⁴, where sodium nitroprusside in aqueous solution at physiological pH spontaneously generates nitric oxide, which interacts with oxygen to produce nitrite ions that can be estimated using Griess reagent. Scavengers of nitric oxide compete with oxygen leading to reduced production of nitrite ions. For the experiment, sodium nitroprusside (10 mM) in phosphate buffered saline was mixed with a concentration of the compound (1 mL; 20–100 μM) and incubated at room temperature for 150 min. After the incubation period, 0.5 mL of Griess reagent containing 1% sulfanilamide, 2% H₃PO₄ and 0.1% N-(1-naphthyl) ethylenediaminedihydrochloride were added. The absorbance of the chromophore formed was measured at 546 nm.

Estimation of total antioxidant capacity

Total antioxidant was determined by phosphomolybdenum method⁵ followed by Samples and standard (1 ml) was mixed with 2 ml of reagent solution [ammonium molybdate (4 mM), sodium phosphate (28 mM) and sulphuric acid (0.6 M)]. All the reaction mixtures were incubated at 95 °C for 90 min. The absorbance was measured at 695 nm.

For the above assay, all of the tests were run in triplicate and various concentrations of the compounds were used to fix a concentration at which the compounds showed in and around 50 % of activity. In addition, the percentage of activity was calculated using the formula: % of suppression ratio = $[(A_0 - A_c)/A_0] \times 100$. A₀ and A_c are the absorbance in the absence and presence of the tested compounds, respectively. The IC₅₀ (half maximal inhibitory concentration) is a measure the effectiveness of the substance in inhibiting a specific biological or biochemical function. The 50 % activity (IC₅₀) can be calculated using the percentage of activity. All experimental results were expressed as the mean and (±) standard deviation (SD) of triplicate determinations.

Cytotoxicity studies

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay⁶

MTT, upon reduction by NAD(P)H-dependent cellular oxidoreductase enzymes present in the cytoplasm of metabolically active cells, forms formazan as a purple insoluble product. The amount of formazan estimated by a spectral method correlates with the number of live cells and provides a quantitative measurement of the cytotoxicity of the compound. The IC₅₀ values were obtained from nonlinear regression using GraphPad Prism 5.⁷ About 6000 cells of MCF-7 (human breast cancer cells) were taken in each well of a 96-well culture plate and incubated for 24 hours in a CO₂ incubator. After incubation, different concentrations (6, 12, 25, 50, 100 μM) of the compounds dissolved in DMSO were added to the cells. After appropriate incubation time (24 h for complexes and ligands), the wells were treated with 20 μl MTT (5 mg/ml phosphate-buffered saline, PBS) and incubated for 3 h. The purple formazan crystals obtained were dissolved in 200 μl DMSO and the absorbance was measured at 570 nm in Molecular Devices Spectra Max M5 plate reader. Data were obtained as the average of three independent sets of experiments, all performed in triplicate for each concentration.⁶

Morphological Changes of MCF7 cells using phase contrast inverted microscope

Observation of morphological changes of apoptotic cells was performed according to the method with slight modifications.⁸ Briefly, MCF-7 cells were seeded into 24-well plate and incubated overnight to attach. Then, the cells were treated with or without test compounds (control) at different concentrations of 12 and 25 μM for complexes 1-4 was incubated 24h at 37°C with 5% CO₂. The morphological changes of the cells were observed using an inverted light microscope at 100 X magnification.

Acridine orange/ethidium bromide staining

Acridine orange/ethidium bromide staining was carried out by the method of Gohelet *al.*⁹ and MCF-7 cells were plated in a 24-well plates. They were allowed to grow at 37 °C in a humidified CO₂ incubator. Then the cells were treated with IC₅₀ concentrations of complexes 1 and 4 for 24 h. The culture medium was aspirated from each well and the cells were gently rinsed twice with PBS at room temperature. Then equal volumes of cells from control and metal complexes treated were mixed with 100 ml of dye mixture (1:1) of acridine orange and ethidium bromide and viewed immediately by fluorescence microscopy.

References

- 1 (a) A. Wolfe, G.H. Shimer and T. Meehan, *Biochemistry*, 1987, **26**, 6392.
(b) G. Cohen and H. Eisenberg, *Biopolymers*, 1969, **8**, 45.
- 2 S. Sathiyaraj, K. Sampath, R. J. Butcher, R. Pallepogu and C. Jayabalakrishnan, *Eur. J. Med. Chem.*, 2013, **64**, 81.
- 3 M. R. Szabo, C. Idtoiu, D. Chambre, and A. X. Lupea, *Chemistry and Materials science*, 2014, **61**, 214.
- 4 L.C. Green, D.A. Wagner, J. Glogowski, P.L. Skipper, J. S. Wishnok and S.R. Tannenbaum, *Anal. Biochem.*, 1982, **126**, 131.
- 5 P. Prieto, M. Pineda, and M. Aguilar, *Anal. Biochem.*, 1999, **269**, 337.
- 6 T. Mossman, *J. Immunol. Methods*, 1983, **65**, 55.
- 7 H. J. Motulsky, Prism 5 Statistics Guide, GraphPad Software Inc., San Diego, CA 2007. <http://www.graphpad.com>.
- 8 P. Moongkarndi, N. Kosem, S. Kaslungka, O. Luanratana, N. Pongpan and N. Neungton, *J. Ethnopharmacol.*, 2004, **90**, 161.
- 9 A. Gohel, M. B. McCarthy and G. Gronowicz, *Endocrinology*, 1999, **140**, 5339.




Fig. S1¹H-NMR spectrum of [H-Fcm-tsc] (HL¹)




Fig. S2 ¹H-NMR spectrum of [Pd(4(2Hbp-1-ca)(PPh₃)Cl)] (1)




Fig. S3 ¹H-NMR spectrum of [H-Fcm-mtsc] (HL²)




Fig. S4 ¹H-NMR spectrum of [Pd(4(2Hbmp-1-ca)(PPh₃)Cl)] (2)




Fig. S5 ¹H-NMR spectrum of [H-Fcm-etsc] (HL³)




Fig. S6 $^1\text{H-NMR}$ spectrum of $\text{Pd}(4(2\text{Hbep-1-ca})(\text{PPh}_3)\text{Cl}]$ (3)




Fig. S7 $^1\text{H-NMR}$ spectrum of $[\text{H-Fcm-ptsc}]$ (HL^4)




Fig. S8 ¹H-NMR spectrum of [Pd(4(2Hbpp-1-ca)(PPh₃)Cl)] (4)




Fig.S9 ¹³C-NMR spectrum of [H-Fcm-tsc] (HL¹)




Fig. S10 ¹³C-NMR spectrum of [Pd(4(2Hbp-1-ca)(PPh₃)Cl)] (1)




Fig.S11 ¹³C-NMR spectrum of [H-Fcm-mtsc] (HL²)




Fig. S12 ¹³C-NMR spectrum of [Pd(4(2Hbmp-1-ca)(PPh₃)Cl)] (2)





Fig.S13 ¹³C-NMR spectrum of [H-Fcm-etsc] (HL³)






Fig. S14 ^{13}C -NMR spectrum of $[\text{Pd}(4(2\text{Hbep-1-ca})(\text{PPh}_3)\text{Cl})]$ (**3**)




Fig.S15 ^{13}C -NMR spectrum of $[\text{H-Fcm-ptsc}]$ (**HL⁴**)




Fig. S16 ^{13}C -NMR spectrum of $[\text{Pd}(4(2\text{Hbpp-1-ca})(\text{PPh}_3)\text{Cl})]$ (4)




Fig. S17 ESI-MS spectrum of [Pd(4(2Hbp-1-ca)(PPh₃)Cl] (**1**)




Fig. S18 ESI-MS spectrum of [Pd(4(2Hbmp-1-ca)(PPh₃)Cl] (**2**)






Fig. S19 ESI-MS spectrum of [Pd(4(2Hbpp-1-ca)(PPh₃)Cl)] (4)







Fig. S20 Synchronous spectra of BSA (10 μM) in the absence and presence of complexes **1-4** (0-100 μM) in the wavelength difference of $\Delta\lambda = 60$ nm.